Effect of halothane on lung carcinoma cells A 549.
The halogenated hydrocarbons, such as halothane, are widely used as anesthetics in clinical practice; however their application is often accompanied with metabolic, cardiovascular and respiratory complications. One of the possible factors for this negative outcome might be the severe toxicity of these agents. In this paper, we investigate in vitro effects of halothane on human lung carcinoma A 549 cells, namely on their cytotoxicity, adhesive properties and metabolic activity. The cytotoxicity response of lung carcinoma A 549 cells to halothane was determined by lactate dehydrogenase (LDH) assay (for cytotoxicity), by detachment assay after adhesion to type IV collagen (for cell adhesive properties) and by surface tension measurements of culture medium (for cell metabolic activity). Regarding the cytotoxicity, the determined maximal non-toxic concentration of halothane on A 549 cells, given here as volume percentages (vol.%) was 0.7 vol.% expressed as aqueous concentration in the culture medium. Direct measurement of the actual halothane concentration in the culture medium showed that 0.7 vol.% corresponds to 1.05 mM and 5.25 aqueous-phase minimum alveolar concentration (MAC). Concentrations equal or higher than 1.4 vol.% (2.1 mM; 10.5 MAC) of halothane provoked complete detachment (cell death), or reduction of initial adhesion to collagen IV in half of the cell population. Surfactant production of A 549 cells, registered up to 48 h after halothane treatment, was inhibited by halothane concentrations as low as 0.6 vol.% (0.9 mM; 4.5 MAC). Our results demonstrate that sub toxic halothane concentrations of 0.6 vol.% inhibits surfactant production; concentrations in the range 0.8-1.4 vol.% induce membrane damages and concentrations equal and higher than 1.4 vol.%--cell death of approximately 50% of the cells.
Valtcheva
Ralitza
R
Department of Cell biology, Faculty of Biology, Sofia University, St. Kliment Ohridski, 8 Dragan Tsankov blv, 1164 Sofia, Bulgaria.
Stephanova
Elena
E
Jordanova
Albena
A
Pankov
Roumen
R
Altankov
George
G
Lalchev
Zdravko
Z
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D018685:Anesthetics, Inhalation / Q000633:toxicity*; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor / Q000187:drug effects; D003470:Culture Media / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D006221:Halothane / Q000032:analysis / Q000633:toxicity*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011663:Pulmonary Surfactants / Q000378:metabolism; D013500:Surface Tension / Q000187:drug effects
D018685:Anesthetics, Inhalation; D003470:Culture Media; D011663:Pulmonary Surfactants; D007770:L-Lactate Dehydrogenase; D006221:Halothane